clinic
applic
sirnabas
therapeut
outsid
liver
hinder
ineffici
deliveri
sirna
effector
molecul
extrahepat
organ
cell
interest
understand
paramet
enabl
rnai
activ
vivo
necessari
develop
systemat
approach
identifi
cell
within
tissu
permiss
oligonucleotid
intern
activ
present
studi
evalu
distribut
activ
within
lung
chemic
stabil
sirna
character
celltyp
tropism
structureact
relationship
demonstr
intratrach
deliveri
fulli
modifi
sirna
rnaimedi
target
knockdown
lung
cell
dendrit
cell
alveolar
macrophag
alveolar
epitheli
cell
final
use
allergeninduc
model
lung
inflamm
demonstr
capac
inhal
sirna
induc
target
knockdown
dendrit
cell
amelior
lung
patholog
rnai
technolog
offer
abil
silenc
virtual
express
mrna
includ
molecular
target
causal
human
diseas
amen
convent
approach
clinic
develop
small
interf
rna
sirna
base
therapeut
outsid
liver
limit
primarili
poor
bioavail
extrahepat
tissu
cell
type
interest
deliv
system
sirna
formul
within
lipid
nanoparticl
carri
hepatocytespecif
target
ligand
trigger
nearcomplet
highli
specif
mrna
silenc
numer
target
liver
welltoler
dose
certain
indic
local
deliveri
sirna
eg
mucos
intraocular
intrathec
may
desir
standard
intraven
subcutan
administr
may
enabl
higher
oligonucleotid
concentr
relev
tissu
protect
system
nucleas
howev
previou
studi
local
sirna
administr
yield
variabl
unpredict
result
limit
clinic
relev
confound
result
aris
primarili
need
achiev
suffici
metabol
stabil
sirna
preserv
intrins
rnai
activ
avoid
potenti
sirnainduc
innat
immun
respons
histor
challeng
field
overal
still
gener
pauciti
understand
paramet
influenc
sirna
bioavail
efficaci
nonliv
tissu
lung
access
tissu
attract
therapeut
target
unmet
medic
need
focu
sever
rnai
studi
recent
year
human
unmodifi
sirna
target
rsv
nucleocapsid
n
gene
advanc
phase
iib
clinic
trial
miss
primari
endpoint
nevertheless
show
clinic
meaning
treatment
effect
preclin
studi
specif
demonstr
vivo
use
mismatch
control
theoret
protect
effect
innat
immun
activ
rule
immunogen
nonspecif
sirna
lack
antivir
efficaci
chemic
modifi
form
detect
immunostimulatori
capac
retain
full
activ
vivo
furthermor
rnai
mechan
action
demonstr
vivo
detect
sitespecif
cleavag
product
rsv
mrna
addit
studi
report
inhal
nake
sirna
efficaci
parainfluenza
viru
piv
well
lung
xenograft
tumor
growth
group
describ
intratrach
intranas
deliveri
sirna
target
effector
inflamm
like
improv
diseas
outcom
rodent
although
direct
target
engag
pathologyrelev
cell
conclus
demonstr
contrast
report
moscho
et
al
conclud
intratrach
deliv
sirna
could
intern
cell
therefor
lack
efficaci
lung
importantli
note
lung
deliveri
report
far
use
unmodifi
partial
modifi
sirna
expect
poor
metabol
stabil
better
translat
abund
preclin
studi
clinic
necessari
fulli
understand
ident
cell
lung
permiss
oligonucleotid
intern
activ
airway
lung
compos
wide
varieti
cell
specif
role
patholog
homeostasi
includ
special
epitheli
cell
vascular
endotheli
cell
differ
hematopoiet
cell
subpopul
complex
immunolog
function
particular
lung
immun
compart
contain
pharmacolog
target
modul
therapeut
benefit
asthma
copd
autoimmun
diseas
flow
cytometri
cell
sort
technolog
allow
better
definit
lung
parenchym
cell
resid
leukocyt
popul
present
studi
taken
advantag
technolog
particularli
advanc
fulli
modifi
sirna
provid
except
metabol
stabil
evalu
distribut
activ
sirna
within
lung
systemat
character
celltyp
tropism
structureact
relationship
sirna
chemistri
final
use
allergeninduc
model
lung
inflamm
demonstr
capac
inhal
sirna
amelior
lung
patholog
sirna
sequenc
chemic
modif
scheme
use
manuscript
found
figur
construct
except
oh
contain
extens
fluoromethoxi
ribos
modif
positionspecif
phosphorothio
backbon
linkag
known
improv
uptak
stabil
bioavail
sirna
addit
chemistri
util
includ
invert
abas
ribos
cap
end
passeng
sens
strand
stabl
phosphat
mimic
recent
describ
modif
pattern
use
studi
particularli
guid
strand
larg
conserv
specif
pattern
use
major
impact
rel
stabil
rnai
activ
evalu
rnaimedi
activ
induc
mous
lung
local
sirna
administr
gener
sirna
two
ubiquit
express
gene
target
bcatenin
syndrom
antigen
b
ssb
sequenc
chemic
modif
scheme
use
manuscript
found
figur
synthes
sirna
dissolv
pb
deliv
without
conjug
cellular
uptak
agent
eg
cholesterol
associ
transfectionpromot
reagent
eg
liposom
intratrach
use
microspray
aerosol
analysi
total
lung
rna
day
posttreat
reveal
signific
target
knockdown
dosedepend
fashion
mgkg
figur
importantli
crossov
control
demonstr
effect
observ
case
target
gene
demonstr
mrna
knockdown
occur
rnaimedi
mechan
nonspecif
inflammationrel
event
vivo
activ
sirna
absenc
lipid
polym
transfect
agent
conclus
demonstr
liver
far
requir
conjug
hepatocytetarget
ligand
like
multival
nacetylgalactosamin
lipophil
moieti
like
cholesterol
moscho
et
al
report
intratrach
administ
antisens
oligonucleotid
escap
lung
blood
circul
accumul
induc
target
knockdown
liver
correspondingli
observ
liver
silenc
sirna
lung
administr
importantli
knockdown
observ
sirna
molecul
conjug
multimer
galactos
nacetyl
galnac
figur
overal
result
indic
presenc
cell
lung
passiv
take
sirna
ie
without
celltarget
ligand
permiss
rnai
activ
furthermor
result
demonstr
potenti
lungadminist
sirna
effect
distal
tissu
like
liver
chemic
sirna
modif
requir
avoid
immun
activ
lung
induc
target
gene
knockdown
immunostimulatori
activ
doublestrand
rna
caus
primarili
activ
type
interferon
pathway
endosom
tolllik
receptor
howev
sirnainduc
immunostimul
extens
diminish
care
select
nucleotid
sequenc
avoid
certain
dinucleotid
motif
chemic
modif
confirm
fulli
modifi
sirna
design
strategi
prevent
activ
mucos
immun
mice
dose
intratrach
sequenceident
sirna
carri
extens
chemic
modif
fome
larg
unmodifi
oh
shown
figur
silenc
activ
trigger
chemic
modifi
sirna
significantli
higher
suggest
depend
oligonucleotid
stabil
lung
rnai
activ
compar
abil
oh
induc
inflamm
time
cours
analysi
includ
e
coli
lipopolysaccharid
lp
posit
control
demonstr
neutrophilia
figur
proinflammatori
cytokin
elev
bal
fluid
figur
induc
oh
abrog
modif
includ
activ
sirna
intranas
lp
administr
induc
strong
inflammatori
respons
signific
effect
level
data
demonstr
modif
introduc
sirna
design
success
prevent
activ
innat
immun
system
lung
rule
possibl
nonspecif
inflamm
contribut
decreas
target
mrna
level
first
step
character
suborgan
distribut
sirna
examin
lung
histolog
section
mice
dose
fluoresc
label
sirna
target
analysi
mrna
level
show
conjug
fluoresc
label
affect
rnai
activ
sirna
data
shown
studi
reveal
earli
h
dose
intratrach
deliveri
sirna
local
primarili
muscular
layer
surround
central
arteri
signific
local
also
endotheli
cell
submucos
layer
upper
airway
alveolar
epithelia
figur
distribut
pattern
subsequ
lost
intens
stain
arteri
region
significantli
decreas
h
postdos
figur
h
fluoresc
signal
observ
alveolar
macrophag
figur
importantli
detect
fluoresc
sirna
bronchial
epithelium
time
point
analyz
higher
magnif
analysi
h
postdos
reveal
sirna
local
lamina
propria
smooth
muscl
layer
area
surround
bronchi
bronchiol
figur
howev
sirna
design
smoothmusclespecif
gene
marker
fail
induc
gene
knockdown
activ
total
lung
rna
level
suggest
product
sirna
deliveri
smooth
muscl
cell
data
shown
taken
togeth
data
suggest
chemic
modifi
unconjug
sirna
distribut
passiv
lung
cell
primarili
alveolar
macrophag
alveolar
epithelia
directli
assess
sirna
distribut
activ
diseaserelev
lung
cell
subpopul
develop
tissu
disruptioncellsort
protocol
similar
one
describ
moscho
et
al
mous
lung
enzymat
dissoci
result
singlecel
lung
mix
suspens
sequenti
fraction
use
mac
microbead
technolog
cell
cell
neg
cell
subset
figur
previous
shown
cell
subset
contain
dendrit
cell
alveolar
macrophag
easili
identifi
differ
autofluoresc
analysi
cell
subset
contain
hematopoiet
cell
confirm
lack
cell
demonstr
success
cell
separ
approach
stain
panendotheli
epitheli
cell
marker
segreg
neg
cell
subset
nonhematopoiet
cell
neg
cell
contain
epitheli
cell
repres
lung
cell
endotheli
cell
neg
neg
cell
fibroblast
smooth
muscl
cell
analysi
mrna
level
cell
subset
isol
day
mgkg
sirna
dose
reveal
signific
differ
sirna
activ
differ
lung
cell
type
contrast
studi
wwwmoleculartherapyorg
moscho
et
al
observ
strong
target
mrna
knockdown
alveolar
macrophag
dendrit
cell
far
higher
observ
start
total
lung
cell
suspens
addit
lower
signific
reproduc
knockdown
detect
nonhematopoiet
neg
cell
subset
signific
activ
observ
hematopoiet
cell
figur
secondari
observ
analysi
cell
contain
half
target
mrna
popul
reflect
intrins
differ
tissuespecif
gene
express
pattern
tissu
sirna
level
measur
stemloop
qrtpcr
figur
significantli
higher
subset
compar
total
lung
cell
suspens
correl
well
strong
rnai
activ
observ
subpopul
contrast
neg
nonhematopoiet
popul
show
lower
reproduc
rnai
activ
contain
lower
sirna
total
lung
cell
suspens
tissu
sirna
measur
also
correl
well
accumul
fluoresc
sirna
alveolar
macrophag
figur
taken
togeth
result
demonstr
differ
cell
type
within
b
c
lung
differenti
permiss
sirna
intern
rnai
activ
attach
polyethylen
glycol
peg
polym
common
procedur
drug
research
aim
improv
pharmacokinet
small
molecul
biolog
sirna
pegyl
passeng
strand
shown
irrelev
intrins
silenc
activ
prolong
system
circul
reason
higher
molecular
weight
pegyl
sirna
could
potenti
increas
lung
retent
activ
reduc
escap
blood
capillari
assess
possibl
synthes
two
sirna
carri
peg
moieti
differ
molecular
weight
configur
analysi
target
mrna
level
day
postdos
reveal
despit
carri
ident
guid
strand
passeng
strand
pegyl
render
sirna
inact
figur
interestingli
loss
activ
correl
lower
sirna
content
lung
subset
analyz
fact
support
hypothesi
pegyl
sirna
content
neg
cell
popul
higher
control
sirna
figur
result
suggest
peg
modif
result
chang
intracellular
traffick
mechan
prevent
rnai
activ
sirna
activ
distribut
lung
independ
dose
aerosol
intratrach
deliveri
via
microspray
aerosol
allow
homogen
drug
distribut
lower
airway
effort
achiev
sirna
deliveri
upper
airway
epithelium
mice
dose
liquid
bolu
intratrach
instil
pipett
howev
result
reveal
differ
target
gene
knockdown
isol
cell
subset
indic
microspray
instil
deliveri
result
similar
sirna
distribut
activ
lung
importantli
unchang
gene
target
knockdown
neg
popul
indic
bronchial
epitheli
cell
permiss
rnai
least
sirna
structur
class
figur
sirna
activ
observ
nonhematopoiet
lung
cell
occur
primarili
epitheli
cell
establish
ident
cell
lung
nonhematopoiet
neg
subset
permiss
sirna
activ
isol
line
indic
mean
se
p
p
p
versu
pbstreat
cell
subset
p
p
p
versu
vpdose
subset
ns
signific
wwwmoleculartherapyorg
molecular
therapi
nucleic
acid
vol
june
endotheli
defin
neg
epitheli
neg
neg
cell
subset
puriti
use
fluorescenceactiv
cell
sorter
fac
mous
lung
day
sirna
dose
analysi
mrna
express
panendotheli
marker
demonstr
effect
separ
endotheli
cell
mix
lung
popul
figur
likewis
analysi
club
cell
pdpn
alveolar
epithelium
alveolar
epithelium
ii
demonstr
success
separ
subset
epitheli
cell
lungcellspecif
marker
ciliat
cell
smooth
muscl
cell
goblet
cell
segreg
epitheli
endotheli
subset
indic
cell
express
marker
present
tripleneg
neg
neg
neg
subset
data
shown
analysi
mrna
level
reveal
target
mrna
knockdown
epitheli
endotheli
cell
subset
figur
agreement
local
fluoresc
label
sirna
alveolar
epitheli
cell
previous
discuss
figur
despit
higher
knockdown
observ
epitheli
cell
sirna
level
higher
epitheli
cell
subset
figur
suggest
differ
rnai
activ
endotheli
epitheli
cell
like
caus
differenti
subcellular
traffick
cytosol
partit
ultim
determin
sirna
concentr
access
rnainduc
silenc
complex
risc
previou
studi
establish
role
dendriticcellexpress
downstream
amplifi
allergentrigg
lung
inflamm
cascad
exampl
administr
block
monoclon
antibodi
inhibit
respons
ovalbumin
ova
induc
allerg
lung
inflamm
mous
model
importantli
inhibitori
effect
occur
recal
primari
effector
respons
suggest
like
play
major
role
vivo
reactiv
memori
respons
evalu
effect
rnaibas
technolog
modul
lung
patholog
test
sirna
phenotyp
model
mice
sensit
intraperiton
inject
ova
protein
plu
alum
day
challeng
intranas
solubl
ova
day
two
sirna
mgkg
dose
given
day
lung
collect
day
assess
knockdown
recal
respons
figur
treatment
control
mice
dose
nonspecif
sirna
pb
expect
mrna
level
total
lung
almost
undetect
sensitizedonli
challeng
mice
upregul
upon
intranas
challeng
importantli
mice
dose
sirna
show
signific
downregul
target
gene
control
sirna
effect
figur
expect
due
effect
modul
cell
memori
respons
sirnatr
mice
reduc
express
signific
lower
level
cytokin
mrna
total
lung
figur
protein
bronchoalveolar
lavag
bal
fluid
figur
serum
antigenspecif
immunoglobulin
e
ige
also
lower
mice
demonstr
inhibit
recal
respons
figur
detect
statist
signific
decreas
lung
eosinophil
recruit
togeth
result
recapitul
publish
studi
analyz
effect
block
antibodi
demonstr
capac
local
sirna
deliveri
modul
biolog
outcom
lung
induct
rnai
activ
depend
endogen
cellular
machineri
intern
engag
cytosol
rna
induc
silenc
complex
risc
rna
duplex
unravel
guid
antisens
strand
bound
protein
endonucleas
respons
sitespecif
degrad
target
mrna
sirna
larg
polar
nonmembraneperm
molecul
typic
requir
lipid
polymerbas
transfect
agent
target
ligand
achiev
effici
cellular
uptak
intern
cytosol
releas
singlestrand
oligonucleotid
heavili
modifi
phosphorothio
backbon
occur
without
use
special
deliveri
vehicl
remain
ineffici
process
well
establish
howev
cell
type
far
permiss
other
oligonucleotid
deliveri
make
necessari
character
sirna
biodistribut
cellular
resolut
rather
sole
organ
level
earli
studi
analyz
intratrach
intranas
sirna
deliveri
report
downregul
mrna
target
induc
biolog
effect
anim
model
lung
patholog
suggest
presenc
cell
lung
permiss
sirna
intern
activ
particular
demonstr
show
antivir
activ
via
rnai
mechan
fail
advanc
clinic
find
contrast
later
studi
conclud
nake
sirna
deliv
product
lung
cell
topic
administr
mediat
rna
interfer
furthermor
mani
initi
report
sirna
lung
activ
attribut
nonspecif
effect
particularli
activ
innat
immun
respons
conflict
report
underscor
need
systemat
approach
character
intrins
sirna
permiss
cell
lung
address
problem
moscho
et
al
use
tissu
disrupt
cell
sort
conclud
intratrach
deliv
unmodifi
sirna
could
intern
cell
therefor
could
mediat
rnai
activ
lung
studi
chemic
modifi
antisens
oligonucleotid
shown
accumul
alveolar
macrophag
lung
epithelia
induc
target
knockdown
conclus
demonstr
chemic
modifi
sirna
inde
mediat
rnai
activ
multipl
cell
lung
avoid
immun
system
activ
conflict
result
explain
optim
chemic
modif
render
sirna
resist
lung
nucleas
andor
lysosom
degrad
increas
vivo
halflif
facilit
cytosol
releas
respect
correspond
idea
observ
lung
mrna
silenc
highli
depend
chemic
modif
confer
resist
circul
intracellular
nucleas
find
agre
report
extens
chemic
modif
need
intracellular
stabil
sirna
conjug
liver
knowledg
work
present
repres
comprehens
character
lung
sirna
distribut
activ
demonstr
intratrach
deliv
sirna
result
target
knockdown
day
postdos
lung
cell
particularli
cell
dendrit
cell
alveolar
macrophag
alveolar
epithelia
importantli
target
larg
function
group
requir
molecul
achiev
pharmacolog
activ
similar
result
observ
day
postdos
use
sirna
differ
target
ssb
thu
demonstr
sequencespecif
effect
use
bolu
instil
instead
intratrach
deliveri
importantli
unlik
unmodifi
sirna
deliveri
chemic
modifi
sirna
induc
inflamm
lung
induc
mark
histolog
chang
lung
observ
signific
chang
rel
cell
number
stain
pattern
lung
dose
anim
except
increas
autofluoresc
alveolar
macrophag
stemloop
pcr
analysi
reveal
sirna
lung
day
postdos
contain
cell
cell
surpris
cell
subset
highest
target
knockdown
observ
howev
direct
correl
cellular
sirna
content
mrna
knockdown
establish
sinc
epitheli
neg
neg
cell
subset
show
similar
mrna
knockdown
lower
sirna
level
likewis
peg
conjug
abolish
activ
sirna
molecul
actual
induc
signific
increas
cellular
sirna
content
result
clearli
demonstr
cellintrins
differ
sirna
intern
traffick
mechan
regul
oligonucleotid
design
defin
rnai
enabl
cellular
level
multipl
studi
disrupt
signal
axi
employ
dendrit
cell
dc
deplet
approach
demonstr
crucial
role
dcexpress
recal
respons
lung
use
protocol
similar
establish
effect
antibodi
demonstr
intratrach
deliveri
sirna
induc
gene
silenc
within
dccontain
lung
cell
popul
modul
lung
patholog
furthermor
shown
effect
depend
sirna
modif
pattern
employ
demonstr
sirna
stabil
chemic
modif
absolut
requir
vivo
activ
correspond
role
dcexpress
memori
respons
observ
downregul
ige
sirnados
mice
howev
see
statist
signific
decreas
lung
eosinophilia
would
expect
complet
downregul
recal
respons
seshasaye
et
al
propos
studi
protocol
use
two
sensit
dose
instead
one
result
longerlast
effector
respons
fulli
suppress
reagent
consid
possibl
start
challeng
mice
day
second
sensit
dose
comparison
hoshino
et
al
studi
challeng
mice
start
day
second
dose
report
signific
suppress
recal
respons
reagent
therefor
possibl
studi
protocol
longer
prechalleng
period
would
result
even
stronger
downregul
paramet
altern
combin
approach
anoth
agent
target
differ
stage
pathway
could
synergist
protect
effect
systemat
character
sirna
tropism
vivo
activ
describ
togeth
recent
advanc
optim
modif
improv
vivo
potenc
pave
way
develop
newer
sirna
inhal
reagent
human
therapi
primari
sequenc
chemic
modif
scheme
sirna
target
mous
ssb
sirna
control
employ
studi
summar
figur
oligonucleotid
dissolv
dose
ml
pb
anim
sedat
inhal
isofluoran
dose
intratrach
use
microspray
aerosol
high
pressur
syring
penncenturi
anim
dose
sirna
label
fluorophor
thermo
scientif
sacrif
h
postdos
trachea
cannul
teflon
angiocath
cathet
bd
bioscienc
inflat
lung
ml
neutralbuff
formalin
solut
sigmaaldrich
tie
surgic
sutur
lung
excis
immers
addit
neutralbuff
formalin
solut
h
paraffinprocess
section
mm
lung
section
slide
stain
dapi
immedi
imag
imag
acquir
sequenti
mode
blue
dapi
green
autofluoresc
far
fluoresc
label
channel
use
appropri
excit
emiss
set
ariol
system
leica
biosystem
use
leica
microscop
immedi
euthanasia
mous
trachea
cannul
lung
inflat
ml
collagenas
roch
mgml
fetal
bovin
serum
fb
rpmi
solut
lung
excis
conic
tube
addit
collagenas
solut
ml
place
c
water
bath
without
shake
min
incub
cold
pb
ad
ml
vigor
shaken
complet
dissoci
lung
tissu
suspens
filter
strainer
new
conic
tube
mix
ml
cold
red
blood
cell
rbc
lysi
solut
biolegend
cell
immedi
pellet
resuspend
mm
edtapb
ml
filter
mm
strainer
count
vicel
cell
viabil
analyz
dissoci
lung
cell
treat
fc
block
bd
bioscienc
stain
follow
fluorophoreconjug
antibodi
obtain
ebiosci
viabil
assess
livedead
fixabl
nearir
cell
stain
life
technolog
fluorescein
isothiocyan
fitc
conjug
antibodi
employ
help
identifi
autofluoresc
alveolar
macrophag
flow
cytometri
analysi
perform
bd
facscanto
system
cell
suspens
mous
lung
resuspend
ml
cold
sort
buffer
mm
edtapb
contain
fc
block
bd
bioscienc
min
incub
ice
ml
microbead
miltenyi
biotec
ad
incub
ice
anoth
min
cell
wash
resuspend
cold
sort
buffer
ml
fraction
automac
pro
miltenyi
biotec
use
possel
set
cell
positiveselect
fraction
cell
count
lyse
ml
trizol
life
technolog
negativeselect
fraction
mix
ml
microbead
miltenyi
biotec
incub
min
ice
fraction
automac
pro
use
possel
set
cell
positiveselect
fraction
cell
negativeselect
fraction
cell
count
lyse
ml
ml
trizol
respect
cell
subset
puriti
assess
flow
cytometri
analysi
altern
isol
endotheli
epitheli
cell
subset
lung
cell
suspens
stain
viabil
dye
fluorophoreconjug
antibodi
sort
trizol
ls
reagent
life
technolog
use
bd
facsjazz
system
epitheli
cell
subset
identifi
neg
neg
cell
endotheli
cell
identifi
neg
cell
quantif
sirna
uptak
activ
sirna
guidestrand
quantit
perform
stemloop
rtqpcr
total
tissu
homogen
describ
mrna
quantit
total
cellular
rna
extract
trizol
follow
manufactur
instruct
cdna
synthes
high
capac
cdna
revers
transcript
kit
appli
biosystem
taqman
gene
express
assay
purchas
appli
biosystem
analysi
fast
realtim
pcr
system
sampl
run
duplic
rel
mrna
express
level
determin
normal
valu
ppib
mrna
describ
previous
bal
fluid
isol
four
consecut
wash
ml
ml
ml
ml
mm
edtacomplet
proteas
inhibitor
cocktail
roch
ca
mg
free
dulbecco
pb
dpb
fluid
recov
first
two
wash
pool
centrifug
supernat
kept
cytokin
analysi
use
bd
cytometr
bead
array
bd
bioscienc
pellet
cell
pool
cell
addit
two
wash
differenti
count
perform
describ
van
rijt
et
al
balbc
mice
sensit
day
intraperiton
inject
mg
ova
protein
chicken
egg
albumin
sigmaaldrich
emulsifi
mg
imject
alum
adjuv
aluminum
hydroxid
thermo
scientif
pb
day
mice
anesthet
inhal
isofluoran
foran
abbot
challeng
intranas
instil
mg
ova
protein
ml
pb
alon
day
mice
dose
sirna
steril
pb
pb
alon
intratrach
microspray
final
anim
sacrif
h
last
ova
administr
analysi
wwwmoleculartherapyorg
statist
analys
perform
use
prism
softwar
graphpad
softwar
dataset
present
mean
sem
unless
indic
otherwis
signific
differ
two
mean
group
valu
analyz
use
unpair
twotail
student
test
oneway
anova
dunnett
test
analys
two
group
determin
statist
signific
least
asterisk
indic
statist
signific
differ
group
respect
control
group
unless
otherwis
indic
line
